Methylation status of DLEC1 promoter in colorectal cancer patients and its clinical relevance

2010 ◽  
Vol 30 (8) ◽  
pp. 842-845
Author(s):  
Xiao-bing YE ◽  
You-wei ZHANG ◽  
Long-bang CHEN
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Clinical Relevance ◽  
Methylation Status ◽  
Colorectal Cancer Patients

Clinical Relevance of Plasma DNA Methylation in Colorectal Cancer Patients Identified by Using a Genome-Wide High-Resolution Array

2014 ◽  
Vol 22 (S3) ◽  
pp. 1419-1427 ◽  
Author(s):  
Pei-Ching Lin ◽  
Jen-Kou Lin ◽  
Chien-Hsing Lin ◽  
Hung-Hsin Lin ◽  
Shung-Haur Yang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Dna Methylation ◽  
High Resolution ◽  
Cancer Patients ◽  
Clinical Relevance ◽  
Plasma Dna ◽  
Genome Wide ◽  
A Genome ◽  
Colorectal Cancer Patients

Blood-based screening for methylation changes in colorectal cancer patients using novel nanotechnologies.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 384-384
Author(s):  
Nita Ahuja ◽  
Ruby Kwak ◽  
Brian Keeley ◽  
Alejandro Stark ◽  
Angela Anna Guzzetta ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Screening ◽  
Cancer Patients ◽  
Methylation Status ◽  
High Sensitivity ◽  
Single Copy ◽  
Tissue Samples ◽  
Methylation Frequency ◽  
Colorectal Cancer Patients ◽  
Cancer Tissues

384 Background: Identification of blood-based biomarkers for cancer screening is essential in order to develop novel and minimally invasive methods for colorectal cancer screening. Our lab has successfully applied a novel nanotechnology that allows us to detect and amplify a single tumor DNA fragment in a plasma sample. This DNA is tested for methylation of several genes including TFPI2 which has shown to be highly sensitive and specific for the detection colorectal cancer in stool. Methods: Whole blood was obtained from 18 colorectal cancer patients and plasma was isolated. Plasma was processed using Methylation On Beads nanotechnology (MOB) and bisulfate treated. Methylation status was determined via quantitative PCR method. Results: Two genes, TFPI2 and IGFBP3, were detected with a high sensitivity. TFPI2, demonstrated a methylation frequency of 94.4%, which is concordant with the TFPI2 methylation frequency of 99% in primary colorectal cancer tissues. IGFBP3 showed the methylation frequency of 61.1%, which corresponds with the methylation frequency of 52% in retrospective colorectal cancer tissues in previous studies. Quantification using standard curves indicated a single copy level of DNA found in plasma. Conclusions: Blood-based screening is challenging due to extremely low quantities of circulating DNA in blood. Utilizing a novel nanotechnology that detects DNA at a single copy level, the methylation changes in colorectal cancer were successfully detected in plasmas at similar frequencies as in tissue samples. This study has demonstrated the feasablility and applicability to blood-based screening. Future studies will focus on improving the sensitivity and determining the specificity of this method.

Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR

2009 ◽  
Vol 35 (3) ◽  
pp. 262-271 ◽  
Author(s):  
Volker Heinemann ◽  
Sebastian Stintzing ◽  
Thomas Kirchner ◽  
Stefan Boeck ◽  
Andreas Jung
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibodies ◽  
Cancer Patients ◽  
Clinical Relevance ◽  
Kras Status ◽  
Colorectal Cancer Patients

scholarly journals Distinct epigenetic features of tumor-reactive CD8+ T cells in colorectal cancer patients revealed by genome-wide DNA methylation analysis

2019 ◽  
Vol 21 (1) ◽  
Author(s):  
Rui Yang ◽  
Sijin Cheng ◽  
Nan Luo ◽  
Ranran Gao ◽  
Kezhuo Yu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Dna Methylation ◽  
T Cells ◽  
T Cell ◽  
Cancer Patients ◽  
Cd8 T Cells ◽  
Methylation Status ◽  
Effector Memory ◽  
Binding Motif ◽  
Colorectal Cancer Patients

Abstract Background Tumor-reactive CD8+ tumor-infiltrating lymphocytes (TILs) represent a subtype of T cells that can recognize and destroy tumor specifically. Understanding the regulatory mechanism of tumor-reactive CD8+ T cells has important therapeutic implications. Yet the DNA methylation status of this T cell subtype has not been elucidated. Results In this study, we segregate tumor-reactive and bystander CD8+ TILs, as well as naïve and effector memory CD8+ T cell subtypes as controls from colorectal cancer patients, to compare their transcriptome and methylome characteristics. Transcriptome profiling confirms previous conclusions that tumor-reactive TILs have an exhausted tissue-resident memory signature. Whole-genome methylation profiling identifies a distinct methylome pattern of tumor-reactive CD8+ T cells, with tumor-reactive markers CD39 and CD103 being specifically demethylated. In addition, dynamic changes are observed during the transition of naïve T cells into tumor-reactive CD8+ T cells. Transcription factor binding motif enrichment analysis identifies several immune-related transcription factors, including three exhaustion-related genes (NR4A1, BATF, and EGR2) and VDR, which potentially play an important regulatory role in tumor-reactive CD8+ T cells. Conclusion Our study supports the involvement of DNA methylation in shaping tumor-reactive and bystander CD8+ TILs, and provides a valuable resource for the development of novel DNA methylation markers and future therapeutics.

scholarly journals The Differential DNA Hypermethylation Patterns of microRNA-137 and microRNA-342 Locus in Early Colorectal Lesions and Tumours

Biomolecules ◽  
2019 ◽  
Vol 9 (10) ◽  
pp. 519
Author(s):  
Elham Kashani ◽  
Mahrooyeh Hadizadeh ◽  
Vahid Chaleshi ◽  
Reza Mirfakhraie ◽  
Chris Young ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Methylation Status ◽  
Dna Hypermethylation ◽  
Normal Colon Mucosa ◽  
Normal Tissues ◽  
Diagnosis And Prognosis ◽  
Adjacent Mucosa ◽  
Prediction And Prevention ◽  
Colorectal Cancer Patients

Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide, representing 13% of all cancers. The role of epigenetics in cancer diagnosis and prognosis is well established. MicroRNAs in particular influence numerous cancer associated processes including apoptosis, proliferation, differentiation, cell-cycle controls, migration/invasion and metabolism. MiRNAs-137 and 342 are exon- and intron-embedded, respectively, acting as tumour-suppressive microRNA via hypermethylation events. Levels of miRNAs 137 and 342 have been investigated here as potential prognostic markers for colorectal cancer patients. The methylation status of miRNA-137 and miRNA-342 was evaluated using methylation-specific (MSP) polymerase chain reaction (PCR) on freshly frozen tissue derived from 51 polyps, 8 tumours and 14 normal colon mucosa specimens. Methylation status of miRNA-137 and miRNA-342 was significantly higher in tumour lesions compared to normal adjacent mucosa. Surprisingly, the methylation frequency of miR-342 (76.3%) among colorectal cancer patients was significantly higher compared to miR-137 (18.6%). Furthermore, normal tissues, adjacent to the lesions (N-Cs), displayed no observable methylation for miRNA-137, whereas 27.2% of these N-Cs showed miRNA-342 hypermethylation. MiRNA-137 hypermethylation was significantly higher in male patients and miR-342 hypermethylation correlated with patient age. Methylation status of miRNA-137 and miRNA-342 has both diagnostic and prognostic value in CRC prediction and prevention.

Sign in / Sign up

Export Citation Format

Share Document